Sanofi's IMROZ Phase 3 Study Shows Sarclisa With VRd Reduces Risk Of Disease Progression Or Death By 40% In Newly Diagnosed Transplant-Ineligible Multiple Myeloma; First Global Phase 3 Study Of Anti-CD38 With VRd To Improve PFS And Show Deep Responses; Results Presented At ASCO And Published In NEJM
Portfolio Pulse from Benzinga Newsdesk
Sanofi's IMROZ Phase 3 study shows that Sarclisa combined with VRd reduces the risk of disease progression or death by 40% in newly diagnosed transplant-ineligible multiple myeloma patients. This is the first global Phase 3 study of anti-CD38 with VRd to improve progression-free survival (PFS) and show deep responses. The results were presented at ASCO and published in NEJM.
June 03, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's IMROZ Phase 3 study demonstrates significant efficacy of Sarclisa with VRd in reducing disease progression or death by 40% in newly diagnosed multiple myeloma patients. This positive result is likely to boost investor confidence and positively impact the stock price in the short term.
The positive results from the IMROZ Phase 3 study are significant as they demonstrate the efficacy of Sarclisa in combination with VRd, which is likely to enhance Sanofi's product portfolio and market position in oncology. The presentation at ASCO and publication in NEJM further validate the findings, likely leading to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100